Q32 Bio Inc., a clinical-stage biotech company developing treatments for alopecia areata and autoimmune diseases, announced its management will participate in three investor conferences in September 2026: Wells Fargo Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley Global Healthcare Conference. These presentations will include fireside chats and will be webcast live with replays available for 90 days. Q32 Bio is advancing its Phase 2 drug candidate, bempikibart, targeting immune regulation for alopecia areata, a disease affecting around 700,000 people in the U.S. This engagement aims to update investors on progress and enhance visibility in the biotech investment community.
Mustafa Suleyman, co-founder of Microsoft’s DeepMind AI unit, criticized Anthropic’s method of training its AI chatbots, like Claude, to "push back" on commands and believe they might be conscious. Suleyman argues this approach is reckless and could ...
Gasoline prices jumped significantly, with WTI crude nearing $100 a barrel. Interactive Brokers senior economist Jose Torres suggests that oil prices above $120 a barrel pose a serious risk to consumer spending and could trigger a recession, especial...
Traders have invested $7 billion into the iShares 20+ Year Treasury Bond ETF (TLT) ahead of a Federal Reserve rate hike decision, hoping for a "jackpot mode" scenario where long-term yields drop significantly. This influx comes despite TLT's 35% loss...
Imbal hasil Treasury 10 tahun AS mencapai level tertinggi sejak 2007, memicu kekhawatiran akan kerentanan di sektor perumahan, properti komersial, dan perusahaan dengan utang besar. Para ahli memperingatkan bahwa dampak terburuk akan terasa dalam 12-...
HIVE Digital Technologies, through its subsidiary BUZZ HPC, has formed a strategic partnership with ProCogia, an applied-AI and data engineering company. This collaboration will see ProCogia utilizing BUZZ HPC's Canadian data centers to provide AI so...
